3. Umbruch 4.4..2005 - Online Pot

Cannabinoids in neurodegeneration and neuroprotection 107
cannabinoids in the globus pallidus are associated with a reduction in movement in an animal
model of Parkinson’s disease. FASEB J 14: 1432–1438
132 Brotchie JM (2000) The neural mechanisms underlying levodopa-induced dyskinesia in
Parkinson’s disease. Ann Neurol 47: S105–S114
133 Mazzola C, Micale V, Drago F (2003) Amnesia induced by beta-amyloid fragments is counteracted
by cannabinoid CB1 receptor blockade. Eur J Pharmacol 477: 219–225
134 Herkenham M, Lynn AB, Little MD, Melvin LS, Johnson MR, de Costa DR, Rice KC (1991)
Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro
autoradiographic study. J Neurosci 11: 563–583
135 Factor SA, Firedman JH (1997) The emerging role of clozapine in the treatment of movement
disorders. Mov Disord 12: 483–496
136 Kieburtz K (1999) Antiglutamate therapies in Huntington’s disease. J Neural Transm Suppl 55:
97–102
137 Lastres-Becker I, De Miguel R, Fernández-Ruiz J (2003) The endocannabinoid system and
Huntington’s disease. Curr Drug Target CNS Neurol Disord 2: 335–347
138 Glass M, Faull RLM, Dragunow M (1993) Loss of cannabinoid receptors in the substantia nigra
in Huntington’s disease. Neuroscience 56: 523–527
139 Richfield EK, Herkenham M (1994) Selective vulnerability in Huntington’s disease: preferential
loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol 36: 577–584
140 Glass M, Dragunow M, Faull RLM (2000) The pattern of neurodegeneration in Huntington’s disease:
a comparative study of cannabinoid, dopamine, adenosine and GABA-A receptor alterations
in the human basal ganglia in Huntington’s disease. Neuroscience 97: 505–519
141 Lastres-Becker I, Berrendero F, Lucas JJ, Martin E, Yamamoto A, Ramos JA, Fernández-Ruiz J
(2002) Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid
CB1 receptors in the basal ganglia of a transgenic model of Huntington’s disease. Brain Res 929:
236–242
142 Denovan-Wright EM, Robertson HA (2000) Cannabinoid receptor messenger RNA levels
decrease in subset neurons of the lateral striatum, cortex and hippocampus of transgenic
Huntington’s disease mice. Neuroscience 98: 705–713
143 Page KJ, Besret L, Jain M, Monaghan EM, Dunnett SB, Everitt BJ (2000) Effects of systemic
3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor
binding in the basal ganglia. Exp Brain Res 130: 142–150
144 Lastres-Becker I, Fezza F, Cebeira M, Bisogno T, Ramos JA, Milone A, Fernández-Ruiz J, Di
Marzo V (2001) Changes in endocannabinoid transmission in the basal ganglia in a rat model of
Huntington’s disease. Neuroreport 12: 2125–2129
145 Lastres-Becker I, Gómez M, de Miguel R, Ramos JA, Fernández-Ruiz J (2002) Loss of cannabinoid
CB1 receptors in the basal ganglia in the late akinetic phase of rats with experimental
Huntington’s disease. Neurotox Res 4: 601–608
146 Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH (1996) Mitochondrial
defect in Huntington’s disease caudate nucleus. Ann Neurol 39: 385–389
147 Bizat N, Hermel JM, Humbert S, Jacquard C, Creminon C, Escartin C, Saudou F, Krajewski S,
Hantraye P, Brouillet E (2003) In vivo calpain/caspase cross-talk during 3-nitropropionic
acid-induced striatal degeneration: implication of a calpain-mediated cleavage of active caspase-3.
J Biol Chem 278: 43245–43253
148 Galas MC, Bizat N, Cuvelier L, Bantubungi K, Brouillet E, Schiffmann SN, Blum D (2004)
Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular
mechanisms. Neurobiol Dis 15: 152–159
149 Toulmond S, Tang K, Bureau Y, Ashdown H, Degen S, O’Donnell R, Tam J, Han Y, Colucci J,
Giroux A et al. (2004) Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the
rat malonate model of Huntington’s disease. Br J Pharmacol 141: 689–697
150 Rajkowska G, Selemon LD, Goldman-Rakic PS (1998) Neuronal and glial somal size in the prefrontal
cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch
Gen Psychiatry 55: 215–224
151 Sherer TB, Betarbet R, Greenamyre JT (2001) Pathogenesis of Parkinson’s disease. Curr Opin
Investig Drugs 2: 657–662
152 Sethi KD (2002) Clinical aspects of Parkinson disease. Curr Opin Neurol 15: 457–460
153 Carlsson A (2002) Treatment of Parkinson’s with L-DOPA. The early discovery phase, and a
comment on current problems. J Neural Transm 109: 777–787